Human-derived renal progenitor cell injection(Guangzhou Huayue Renal Regenerative Medicine Technology)

人源肾祖细胞注射液（广州华越肾科再生医学科技）

Report date: 2026/05/22 20:01:29

Base Information

Drug NameHuman-derived renal progenitor cell injection(Guangzhou Huayue Renal Regenerative Medicine Technology)

Drug Alias NameARM-101(Bojimed)

ClassificationCell and gene therapy > Cell therapy > Somatic cell > Nephronic progenitor cell therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsDelayed Graft Function

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesGuangzhou Huayue Renal Regenerative Medicine Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Huayue Renal Regenerative Medicine Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsDelayed Graft Function

Inactive IndicationsN/A

Other Information

ATC CodeN/A